- Paclitaxel/carboplatin plus bevacizumab/erlotinib in the first-line treatment of patients with carcinoma of unknown primary site. Hainsworth, J.D., Spigel, D.R., Thompson, D.S., Murphy, P.B., Lane, C.M., Waterhouse, D.M., Naot, Y., Greco, F.A. Oncologist (2009)